e-Health 2023 Tuesday Plenary Panel

Embracing the possibilities in ML/AI innovation

Tuesday, May 30 from 8:30 – 9:30 am ET. This presentation is sponsored by Novartis.

Machine learning and artificial intelligence (ML/AI) along with augmented reality are shaping and disrupting health systems across the globe. In this exciting plenary session, we will be talking to industry leaders at the forefront of this new era to share their real-world experience with implementing ML/AI in the healthcare setting, debunk the myths about smart technology, and bring a pragmatic lens on how governments and healthcare organizations can embrace this innovation in a safe, trusted, and sustainable manner.



    Aloha McBride brings over 25 years of consulting experience and works with both private and public sector health and wellness entities around the globe. She leads EY’s Global Health sector, defines EY’s global health solutions and works with EY’s regional and local health teams to drive value for clients in the market. Her technical areas of focus include strategic planning, performance improvement, and smart health technology innovation. She holds an MBA from the Thunderbird School of Global Management, a BA in Psychology from the University of California at Berkeley and is PMP and LSS GB certified.


    Rachel Dunscombe is an AI Council member for the UK government and Visiting Professor at Imperial College London, UK, Co-chair of OpenEHR CiC and Chief Industry Advisor of the global health software company Dedalus. She has over 25 years’ experience in the UK National Health Service (NHS), academia, management consulting, and the technology industry. Rachel was previously Chief Executive Officer of the NHS Digital Academy, leading postgraduate education programs both nationally and internationally, and the National Care Alliance Director of Digital and Group Chief Information Officer at the Royal Salford NHS Hospital in Greater Manchester, UK, where she implemented data science and AI approaches to health and wellbeing. Recently she led the KLAS Research Arch Collaborative initiative for electronic health record optimization and supported the ‘Big 4’, consulting in Australia, New Zealand, USA, Europe, and low–middle income countries. Rachel is also Health Lead for the UK government’s artificial intelligence roadmap and contributed to policy including the UK AI strategy.


    With over 20 years of deep pharmaceutical leadership experience across the globe, Andrea Marazzi was appointed Country President, Novartis Pharmaceuticals Canada Inc. on June 1, 2022, where he is responsible for country operations and leadership across the entire organization.

    Prior to this, Mr. Marazzi held the position of Country Pharma Organization Head, Novartis pharmaceuticals, Canada, Inc. where he let the Canadian Pharma Organization through his transformation journey with compelling vision and strategy; set the talent and culture agenda to create an environment conducive to innovation and smart risk-taking for bigger impact; ensured fast and broad access to innovation (8 NME approved in 18 months, including 2 gene therapies); and worked to strengthen the healthcare system through partnerships and high-tech innovation to improve patient comes.

    Before coming to Canada, Mr. Marazzi held the role of Chief Commercial Officer, Europe, based in Novartis’ headquarters in Basel, Switzerland. He was responsible for the strategy and execution of the full portfolio across all European countries, and the five pharmaceutical therapeutic areas, with specific focus on commercial excellence, operationalization of new launches and in-market brands, as well as capability and talent development. In his capacity of CCO, Mr. Marazzi, led the creation of the European Rare Disease organization and succeeded in transforming the business model to be more focused on improving the patient journey and accelerating the time to access for treatments.

    Mr. Marazzi join Novartis in 2001 and held multiple positions of increasing responsibility over the years in Sales and Marketing, Customer Solutions, Brand Strategy, Finance and Strategic Planning in several therapeutic areas and indifferent geographies. His professional aspiration is to drive transformational improvement of healthcare systems, and patient outcomes across the globe, and he is passionate about the role that technology and strategic public-private partnership can play to achieve this mission.

    Mr. Marazzi has a Degree in Economics with Honours from the University of Bocconi in Milan, completed several Harvard Finance programs and has a Post Graduate Certificate in Leadership from the University of Glasgow Caledonian.


    Dr. Bradly Wouters is an internationally recognized leader and cancer researcher. He became Executive Vice President of Science and Research at UHN in 2016 and prior to that served as the Interim Director of Research at the Princess Margaret Cancer Centre since 2014. He joined UHN in 2008 as Senior Scientist and Director of the Princess Margaret Hypoxia Program, and has held faculty appointments at the University of Toronto in the Department of Medical Biophysics and the Department of Radiation Oncology since that time. Prior to joining UHN, Dr. Wouters was Professor and Head of Experimental Radiation Oncology at Maastricht University in the Netherlands. As EVP of Science and Research, Dr. Wouters is focused on creating an environment that incentivizes, facilitates, and rewards excellence in basic, translational, and clinical research across all elements of UHN.


    Nadia Sapiro, President & Founder, Throughline Strategy Inc., is a recognized leader in innovation strategy and research within the health sector. She launched Throughline Strategy in 2016 with a commitment to improving health experiences and outcomes. Nadia’s expertise is in helping clients action research results by exposing and pulling- through bold new points of view that are focused on achieving defined KPIs, and empowering business results in market. With experience in over thirty-two therapeutic areas and a diverse range of specialized healthcare scenarios, Nadia’s facilitation and leadership is laser-focused in uncovering gems for her clients. Nadia excels at helping her clients solve challenging, important problems on urgent timelines.


    Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. The Novartis BIOME is a catalyst for impactful digital collaboration and unites the best of science and technology to create better healthcare solutions and patient experiences at scale. The BIOME reinforces Novartis’s commitment to partner with the entire health ecosystem to jointly innovate and co-develop digital solutions.

STAY UP-TO-DATE on Conference updates

Sign up for our monthly newsletter for more info.